Certara Launches DIDB® Concomitant Meds Navigator, Extending Leadership in Drug Interaction Science
Meet DIDB Concomitant Meds Navigator—an evidence-based tool to identify contraindicated or monitored co-medications and manage…
CertaraSeptember 22, 2025
Certara Launches Libra™: AI-Powered Drug-Induced Liver Injury Prediction Tool
RADNOR, Pa. – September 17, 2025 – Certara, Inc. (Nasdaq: CERT), a global leader in…
CertaraSeptember 17, 2025
Clinical Trials Regulation (EU) No. 536/2014 – The Impact on Annual Safety Reporting
Stay compliant with EU rules for the pharmaceutical industry. Learn about annual safety reports and…
CertaraSeptember 5, 2025
Population Pharmacokinetics for Belantamab Mafodotin Monotherapy and Combination Therapies in Patients with Relapsed/Refractory Multiple Myeloma
Explore comprehensive population pharmacokinetic analyses of belantamab mafodotin, evaluating both monotherapy and combination regimens in…
CertaraAugust 13, 2025
Replacing Traditional TQT Studies with Model-Based Concentration-QTc (C-QTc) Analysis for Cardiovascular Safety in Drug Development
Learn how our experts use concentration-QTc (C-QTc) analysis to replace costly TQT studies, streamline QT…
CertaraAugust 6, 2025
The Medicine Maker: The Biosimulation Generation
The article, The Biosimulation Generation, explores the transformative potential of biosimulation in pharmaceutical R&D as…
Danielle PillsburyJuly 1, 2025
